Search
Search Results
-
Monitoring of over-the-counter (OTC) and COVID-19 treatment drugs complement wastewater surveillance of SARS-CoV-2
BackgroundThe application of wastewater-based epidemiology to track the outbreak and prevalence of coronavirus disease (COVID-19) in communities has...
-
Successes and challenges of China’s health care reform: a four-decade perspective spanning 1985—2023
Chinese health system remains the crucial one for understanding the wider healthcare landscape across the Global South and in particular the leading...
-
Tegileridine: First Approval
Tegileridine (艾苏特) is a small molecule μ-opioid receptor biased agonist developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd for the treatment of...
-
Nedosiran: First Approval
Nedosiran (RIVFLOZA™), a once-monthly subcutaneous small interfering RNA (siRNA) therapy, is being developed by Dicerna Pharmaceuticals, a Novo...
-
Application of two charge transfer complex formation reactions for selective determination of metformin hydrochloride in pharmaceuticals and urine
BackgroundMetformin hydrochloride (MFH) is a biguanide class anti-diabetic drug used to treat type-2 diabetes mellitus. Its reaction with two...
-
Eplontersen: First Approval
Eplontersen (Wainua™) is a ligand-conjugated antisense oligonucleotide directed to TTR , which is being developed by Ionis Pharmaceuticals and...
-
Iptacopan: First Approval
Iptacopan (FABHALTA ® ) is an oral complement Factor B inhibitor developed by Novartis Pharmaceuticals for the treatment of complement-mediated...
-
Alirocumab: Pediatric First Approval
Alirocumab (Praluent ® ), a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor that has been co-developed by Regeneron Pharmaceuticals,...
-
Olutasidenib: First Approval
Olutasidenib (REZLIDHIA TM ), an isocitrate dehydrogenase-1 (IDH1) inhibitor, is being developed by Rigel Pharmaceuticals for the treatment of relapsed...
-
Aprocitentan: First Approval
Aprocitentan (TRYVIO™) is a once-daily oral dual endothelin A (ET A ) and B (ET B ) receptor antagonist developed by Idorsia Pharmaceuticals for the...
-
Befotertinib: First Approval
Befotertinib (Surmana ® ) is an orally administered, highly selective, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase...
-
Vamorolone: First Approval
Vamorolone (AGAMREE ® ) is an oral, selective, dissociative corticosteroid developed by ReveraGen BioPharma and Santhera Pharmaceuticals for the...
-
Village doctors: a national telephone survey of Bangladesh’s lay medical practitioners
BackgroundBangladesh outperforms its Least Developed Country (LDC) status on a range of health measures including life expectancy. Its frontline...
-
Resmetirom: First Approval
Resmetirom (Rezdiffra™) is an oral thyroid hormone receptor-β (THR-β) agonist being developed by Madrigal Pharmaceuticals, Inc., to target the key...
-
Towards mission-driven investment in new antimicrobials? What role for Chinese strategic industrial financing vehicles in responding to the challenge of antimicrobial resistance?
BackgroundAntimicrobial resistance (AMR) causes high levels of global mortality. There is a global need to develop new antimicrobials to replace...
-
“They Merely Prescribe and I Merely Swallow”: Perceptions of Antenatal Pharmaceuticals and Nutritional Supplements Among Pregnant Women in Bamako, Mali
ObjectivesNew international guidelines for antenatal care (ANC) will likely result in an increase in nutritional supplements and preventative...
-
Sunvozertinib: First Approval
Sunvozertinib (舒沃哲 ® ) is an oral, irreversible, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being developed by Dizal...
-
Cantharidin Topical Solution 0.7%: First Approval
Cantharidin (YCANTH™) is a proprietary drug-device combination product containing a formulation of cantharidin 0.7% topical solution (a vesicant...
-
Importance of the intellectual property system in attempting compulsory licensing of pharmaceuticals: a cross-sectional analysis
BackgroundRecently, interest in compulsory licensing of pharmaceuticals has been growing regardless of a country’s income- level. We aim to...
-
Omaveloxolone: First Approval
Omaveloxolone (SKYCLARYS™) is an orally active, small molecule semi-synthetic triterpenoid drug that increases antioxidant activity, which is being...
